GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Liabilities-to-Assets

Arena Pharmaceuticals (FRA:RN3N) Liabilities-to-Assets : 0.14 (As of Dec. 2021)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Arena Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2021 was €98.65 Mil. Arena Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2021 was €694.46 Mil. Therefore, Arena Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2021 was 0.14.


Arena Pharmaceuticals Liabilities-to-Assets Historical Data

The historical data trend for Arena Pharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Liabilities-to-Assets Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.12 0.09 0.09 0.14

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.08 0.11 0.11 0.14

Competitive Comparison of Arena Pharmaceuticals's Liabilities-to-Assets

For the Biotechnology subindustry, Arena Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Liabilities-to-Assets falls into.



Arena Pharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Arena Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Liabilities-to-Assets (A: Dec. 2021 )=Total Liabilities/Total Assets
=98.649/694.464
=0.14

Arena Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2021 is calculated as

Liabilities-to-Assets (Q: Dec. 2021 )=Total Liabilities/Total Assets
=98.649/694.464
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arena Pharmaceuticals  (FRA:RN3N) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Arena Pharmaceuticals Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (FRA:RN3N) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines